Clinical Study Results
Research Sponsor: AstraZeneca AB
Drug Studied: Durvalumab and tremelimumab
Study Title: A study to learn how durvalumab alone or
together with tremelimumab, with
chemotherapy, worked and about
their safety in participants with
advanced small-cell lung cancer
Thank you
Thank you for taking part in the clinical study for the study drugs durvalumab and tremelimumab
with chemotherapy.
You and all of the participants helped researchers learn more about how durvalumab alone or
together with tremelimumab, with chemotherapy, worked to help people with advanced small-
cell lung cancer, also called ES-SCLC.
AstraZeneca sponsored this study and believes it is important to share the results of the study
with you and the public. An independent non-profit organization called CISCRP helped prepare
this summary of the study results for you. We hope it helps you understand and feel proud of
your important role in medical research.
If you participated in the study and have questions about the results, please talk to the study
doctor or staff at your study site.
1